Free Trial
OTCMKTS:CYTR

LadRx (CYTR) Stock Price, News & Analysis

LadRx logo

About LadRx Stock (OTCMKTS:CYTR)

Key Stats

Today's Range
N/A
50-Day Range
$0.09
$0.09
52-Week Range
N/A
Volume
4,000 shs
Average Volume
99,706 shs
Market Capitalization
$4.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

Receive CYTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LadRx and its competitors with MarketBeat's FREE daily newsletter.

CYTR Stock News Headlines

Lord Abbett Developing Growth R3 (LADRX)
Lord Abbett Developing Growth R3
Buffett Dumps $982 Million in BofA Stock—What Does He Know?
Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.
Lord Abbett Developing Growth Fund;R3
LadRx Corporation (LADX)
See More Headlines

CYTR Stock Analysis - Frequently Asked Questions

LadRx Co. (OTCMKTS:CYTR) announced its quarterly earnings results on Friday, August, 9th. The biotechnology company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $0.02.

LadRx shares reverse split on Wednesday, November 1st 2017. The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 31st 2017. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Shares of CYTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that LadRx investors own include Biopharmx (BPMX), SELLAS Life Sciences Group (SLS), Rexahn Pharmaceuticals (REXN), Arrowhead Pharmaceuticals (ARWR), Aurinia Pharmaceuticals (AUPH), Idera Pharmaceuticals (IDRA) and Protalix BioTherapeutics (PLX).

Company Calendar

Last Earnings
8/09/2019
Today
11/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
OTCMKTS:CYTR
Employees
3
Year Founded
N/A

Profitability

Net Income
$-6,700,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.24 per share

Miscellaneous

Free Float
33,834,000
Market Cap
$4.14 million
Optionable
Not Optionable
Beta
1.96

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (OTCMKTS:CYTR) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners